Roche agreed to pay Nurix Therapeutics $700 million upfront for rights to bexobrutideg, positioning the BTK degrader for a potential phase 3 showdown with Eli Lilly’s Jaypirca. The arrangement underscores how quickly the BTK inhibitor-to-degrader competitive landscape is moving, with companies jockeying for differentiation in efficacy and safety profiles. Roche’s investment centers on advancing bexobrutideg into late-stage testing against an established oral BTK asset. The trial design—intended to support direct comparative relevance—could be pivotal for payer and guideline adoption if results differentiate durability, tolerability, or breadth of response. For Nurix, the upfront payment provides substantial non-dilutive runway as it advances its degrader program. For Roche and Lilly, the deal raises the stakes for how the market values next-generation BTK mechanisms and their translation into clinically meaningful outcomes.